
C. Zamora, S.-C. Hung, C. Tomingas, C. Atkinson and M. Castillo

doi: https://doi.org/10.3174/ajnr.A5783
http://www.ajnr.org/content/39/11/2045

This information is current as of November 1, 2023.
Engorgement of Deep Medullary Veins in Neurosarcoidosis: 
A Common-Yet-Underrecognized Cerebrovascular Finding on SWI

C. Zamora, S.-C. Hung, C. Tomingas, C. Atkinson, and M. Castillo

ABSTRACT
SUMMARY: We describe the prevalence and potential significance of deep medullary vein engorgement on SWI in patients with neurosarcoidosis, a finding that has not been described previously. Engorgement was evaluated for possible associations with meningeal or perivascular disease, intracranial hemorrhage, and venous thrombosis, as well as with modified Rankin Scale scores at the time of MR imaging and at follow-up. Deep medullary vein engorgement was seen in 7 of 21 patients and was more common in men. Patients with venous engorgement had a significantly increased incidence of microhemorrhages, perivascular disease, and hydrocephalus. There was no association with the degree of leptomeningeal disease, venous dural sinus thrombosis, or modified Rankin Scale scores. In conclusion, deep medullary vein engorgement was common in our patients with neurosarcoidosis. Although its pathophysiology remains uncertain, it could be related to venous or perivenous abnormalities and may represent a useful secondary finding of cerebrovascular disease.

ABBREVIATION: DMVE = deep medullary vein engorgement

Sarcoidosis is a multisystem disease characterized by formation of noncaseating granulomas. Neurologic manifestations occur in 5% of patients, and mortality can be as high as 11% in the 10 years after initial diagnosis. Neurosarcoidosis has a predilection for perivascular dissemination but can also lead to parenchymal, leptomeningeal, or pachymeningeal disease and may result in a granulomatous angiitis. CNS complications can be diverse and are a function of the nature and extent of tissues involved. Patients can have cranial neuropathies, neuroendocrine dysfunction due to involvement of the pituitary-hypothalamic axis, aseptic meningitis, and myelopathy, among other symptoms. A relatively rare-but-ominous complication is hydrocephalus, which is associated with high mortality. Intracranial hemorrhage is also associated with a poor prognosis and has been reported as a possible sequela of vascular disease.

We have noted that some patients with neurosarcoidosis show a characteristic pattern of deep medullary vein engorgement (DMVE) on SWI, which, to our knowledge, has not been previously described. Our purpose was to report the prevalence of this finding and to establish whether there may be an association with an increased frequency of intracranial hemorrhage, hydrocephalus, or worse neurologic outcomes.

Case Series
Subjects. This retrospective study was approved by our institutional review board, which waived the requirement for informed consent. We searched our electronic medical records system between January 2013 and December 2017 and included all consecutive adult patients (n = 21; 10 men; mean age, 46 ± 14 years) diagnosed with probable or definite neurosarcoidosis based on the criteria of Zajicek et al. We only included patients after 2013 because that was the year when we started using SWI routinely at our institution.

Clinical Variables
General demographic information and clinical characteristics were extracted from the patients’ charts at the time of initial MR imaging. Modified Rankin Scale scores were determined from neurology consults and/or clinical visits at the time of initial MR imaging and at last follow-up.

Imaging Evaluation
Routine multisequence pre- and postcontrast MR imaging scans were evaluated by a neuroradiologist with a Certificate of Added Qualification for the presence of DMVE, leptomeningeal or dural disease, discrete perivascular nodular enhancement (distinct from the engorged vessel), venous thrombosis, hydrocephalus,
and hemorrhage. Microhemorrhages were defined as < 1 cm, and macrohemorrhages were ≥1 cm. Imaging was performed on 1.5T or 3T MR imaging scanners (Avanto, Trio, Skyra, or Aera, Siemens, Erlangen, Germany). Typical parameters for SWI were the following: TE, 40 ms; TR, 49 ms at 1.5T; and TE, 20 ms; TR, 28 ms at 3T; section thickness, 2 mm; flip angle, 15°; FOV, 220 × 220 mm; and matrix size, 256 × 256. Venous thrombosis was evaluated using contrast-enhanced MPRAGE,11 with the following parameters: TE, 2.54 ms; TR, 1900 ms; section thickness, 1 mm; flip angle, 9°; FOV, 250 × 250 mm; matrix size, 256 × 256. Minimum and maximum intensity projections were postprocessed at slice thicknesses of 16 and 12 mm for SWI and MPRAGE, respectively. The median time (interquartile range) from symptom onset to the first MR imaging that included SWI was 36.4 months (9 – 47 months) in the group with DMVE and 28.5 months (3– 47 months) in the group without DMVE.

Statistical Analysis
The normality of data distribution was evaluated with the Shapiro-Wilk test. Distributions were summarized using the mean ± SD or median (interquartile range). Categoric data were expressed as counts or percentages. We used the χ2 and Fisher exact tests for categoric variables and the independent 2-sample t test to compare means of normally distributed data. The Mann-Whitney U test was used to compare variables that were not normally distributed. P values < .05 were considered significant. Statistical analysis was performed with SPSS, Version 24 (IBM, Armonk, New York).

Deep Medullary Vein Engorgement
DMVE was present in 7 (33%) of 21 patients and appeared as enlarged and tortuous medullary veins in a parallel configuration at the level of the corona radiata and a radial orientation around the frontal horns and atria (Fig 1 A and Fig 2 A). This was bilateral and symmetric in all except 1 patient and showed corresponding enhancement on postcontrast MPRAGE (Fig 1 B and Fig 2 A, - B). This was bilateral and symmetric in all except 1 patient and showed corresponding enhancement on postcontrast MPRAGE (Fig 1 B and Fig 2 C). DMVE was more common in men (29%) compared with women (5%, P = .013). There was no significant association between DMVE and patient age (P = .813). DMVE persisted in 5 patients who had follow-up MR imaging despite treatment with corticosteroids or immunomodulatory drugs (mean follow-up duration, 803 ± 549 days).

Intracranial Hemorrhage
Microhemorrhages were present in 7 (33%) of 21 patients and were more prevalent with DMVE (P = .009). Five (71%) of 7 patients with DMVE and 2 (14%) of 14 patients without DMVE had microhemorrhages. There was a single macrohemorrhage in a patient with DMVE who also had microhemorrhages (Fig 3); however, the presence of macrohemorrhage per se was not significant (P = .147). Thirteen patients had MR imaging follow-up at a mean of 803 ±

FIG 1. A 46-year-old man with word-finding difficulties, seizures, and vision loss. SWI minimum-intensity-projection images (A) demonstrates engorged and tortuous deep medullary veins perpendicular to the long axis of the lateral ventricles (arrows), with a fanned configuration around the frontal horns. Thick-slab (12-mm) postcontrast MPRAGE MIP image (B) shows corresponding enhancement (arrowheads). There is also ventriculomegaly.

FIG 2. A 48-year-old man presenting with confusion. SWI minimum-intensity-projection images (A and B) show engorged and tortuous deep medullary veins bilaterally (arrows). Note thinner and relatively faint deep medullary veins in the right frontal lobe (arrowheads in A). There is also corresponding enhancement in the postcontrast MPRAGE MIP image (arrow in C).

FIG 3. A 23-year-old man presenting with severe headaches, nausea, vomiting, and confusion. SWI minimum-intensity-projection image (A) demonstrates engorged deep medullary veins bilaterally (thick arrows) with corresponding enhancement on the postcontrast MPRAGE MIP image (B). There are numerous microhemorrhages bilaterally (arrowheads in A) and a macrohemorrhage in the left temporal lobe (asterisk in C) with surrounding edema seen on the T2 image. Note extensive nodular perivascular enhancement in B (thin arrows).
Basic demographics, symptoms, MRI findings, and modified Rankin Scale scores of patients with neurosarcoidosis

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total (%)</th>
<th>DMVE (+) [%]</th>
<th>DMVE (-) [%]</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>21</td>
<td>7</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Age (mean ± SD) (yr)</td>
<td>46 ± 14</td>
<td>45 ± 13</td>
<td>47 ± 16</td>
<td>.813</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>10/11</td>
<td>6/1</td>
<td>4/10</td>
<td>.013*</td>
</tr>
<tr>
<td>Symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>8 (38%)</td>
<td>4 (57%)</td>
<td>4 (29%)</td>
<td>.346</td>
</tr>
<tr>
<td>Vision loss</td>
<td>5 (24%)</td>
<td>1 (4%)</td>
<td>4 (29%)</td>
<td>.624</td>
</tr>
<tr>
<td>Seizure</td>
<td>3 (14%)</td>
<td>0 (0%)</td>
<td>3 (21%)</td>
<td>.521</td>
</tr>
<tr>
<td>Extremity weakness</td>
<td>3 (14%)</td>
<td>1 (4%)</td>
<td>2 (14%)</td>
<td>1</td>
</tr>
<tr>
<td>Cranial neuropathy</td>
<td>2 (10%)</td>
<td>0 (0%)</td>
<td>2 (14%)</td>
<td>.533</td>
</tr>
<tr>
<td>Gait instability</td>
<td>3 (14%)</td>
<td>2 (29%)</td>
<td>1 (7%)</td>
<td>.247</td>
</tr>
<tr>
<td>Bowel/bladder dysfunction</td>
<td>4 (19%)</td>
<td>3 (43%)</td>
<td>1 (7%)</td>
<td>.088</td>
</tr>
<tr>
<td>Others</td>
<td>4 (19%)</td>
<td>1 (14%)</td>
<td>3 (21%)</td>
<td></td>
</tr>
<tr>
<td>Intracranial hemorrhage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microhemorrhage</td>
<td>7 (33%)</td>
<td>5 (71%)</td>
<td>2 (14%)</td>
<td>.009*</td>
</tr>
<tr>
<td>Macrohemorrhage</td>
<td>1 (5%)</td>
<td>1 (14%)</td>
<td>0 (0%)</td>
<td>.147</td>
</tr>
<tr>
<td>Enhancing disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leptomeningeal</td>
<td>13 (62%)</td>
<td>4 (57%)</td>
<td>9 (64%)</td>
<td>.751</td>
</tr>
<tr>
<td>Pachymeningeal</td>
<td>8 (38%)</td>
<td>3 (43%)</td>
<td>5 (36%)</td>
<td>.751</td>
</tr>
<tr>
<td>Perivascular</td>
<td>3 (14%)</td>
<td>3 (43%)</td>
<td>0 (0%)</td>
<td>.008*</td>
</tr>
<tr>
<td>Venous thrombosis</td>
<td>2 (10%)</td>
<td>1 (14%)</td>
<td>1 (7%)</td>
<td>.599</td>
</tr>
<tr>
<td>Hydrocephalus</td>
<td>6 (29%)</td>
<td>4 (57%)</td>
<td>2 (14%)</td>
<td>.040*</td>
</tr>
<tr>
<td>Modified Rankin Scale score (mean)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At initial MRI (n = 20)</td>
<td>3.2 ± 0.75</td>
<td>2.1 ± 1.5</td>
<td>.125</td>
<td></td>
</tr>
<tr>
<td>At follow-up (n = 18)</td>
<td>2.4 ± 1.1</td>
<td>1.5 ± 1.1</td>
<td>.167</td>
<td></td>
</tr>
</tbody>
</table>

*Statistically significant.

549 days. There was 1 instance of a new microhemorrhage in a patient with DMVE at follow-up, but this occurrence was not statistically significant (P = .118). There was no significant association between intracranial hemorrhage and patient age (P = .704) or perivascular nodular enhancement (P = .186).

**Meningeal and Perivascular Disease**

Thirty (62%) of 21 patients had leptomeningeal enhancement: mild/localized (n = 7), moderate (n = 1), and severe/extensive (n = 5). There was no difference in the overall prevalence of leptomeningeal enhancement between patients with and without DMVE (P = .751). When only patients with leptomeningeal enhancement were considered, there was no difference in the presence of severe leptomeningeal disease between patients with and without DMVE (P = .569). There was also no difference in the prevalence of dural sarcoidosis between patients with and without DMVE (P = .751). Areas of discrete perivascular nodular enhancement were found in 3 (43%) of 7 patients with DMVE and were not seen in those without DMVE (P = .008). When present, these tended to be scattered and isolated except for 1 patient with extensive disease (Fig 3).

**Venous Thrombosis**

There was 1 patient without DMVE who had thrombosis of the superior sagittal sinus and 1 patient with DMVE who had a nonocclusive chronic thrombus in the torcular (P = .599). Although there was no definite cortical or deep cerebral venous thrombosis, we noticed a relative paucity of cortical veins along the cerebral hemispheres in some patients. To account for this as a potential cause for the engorgement, we compared the number of cortical veins at the level of the body of the lateral ventricles between patients with and without DMVE and there was no significant difference (P = .707).

**Hydrocephalus**

Hydrocephalus was present in 6 (29%) of 21 patients and was significantly more common in patients with DMVE (4 of 7 patients, 57%) than in those without (2 of 14 patients, 14%; P = .04). There was no significant association between hydrocephalus and patient age (P = .222), leptomeningeal enhancement (P = .201), or perivascular nodular enhancement (P = .844). A summary of imaging variables is presented in the Table.

**Clinical Characteristics and Neurologic Status**

As can be seen in the Table, symptoms were similar in both groups: Patients without DMVE presented with headaches (n = 4), vision loss (n = 4), seizures (n = 3), extremity weakness (n = 2), cranial neuropathies (n = 2), gait instability (n = 1), hypopituitarism (n = 1), memory issues (n = 1), hypothyroidism (n = 1), hypogonadism (n = 1), hypothyroidism (n = 1), and word-finding difficulties (n = 1).

Modified Rankin Scale scores were obtained at the time of first MR imaging in 20 of 21 patients. In 1 patient, information on neurologic status was not available. Mean scores were higher (worse) in patients with DMVE (3.2 ± 1.5), but the difference was not significant (P = .125). Of 18 patients available for clinical follow-up (mean follow-up duration, 725 ± 551 days), mean scores were also higher in those with DMVE; however, the difference was not significant (P = .167).

**Laboratory Findings**

Because this was a retrospective study, laboratory results at the time of scanning were limited. CSF analysis in 3 patients with DMVE and 5 patients without DMVE showed no significant differences in angiotensin-converting enzyme (P = .393) or protein (P = .786) levels or pleocytosis (P = .464). The CSF angiotensin-converting enzyme level was elevated in 1 patient with DMVE and 1 patient without DMVE, and the CSF protein level was elevated in 2 of 3 patients in the first group and 4 of 5 patients in the second group. The serum angiotensin-converting enzyme was available for 2 patients with DMVE and 7 patients without DMVE and was within normal limits except for 1 patient in each group.

**DISCUSSION**

Deep medullary veins constitute the major draining route of cerebral white matter. They have a typical perpendicular arrangement relative to the long axis of the lateral ventricles and a radial
distribution along the atria and frontal horns, with a fine and uniform caliber and several zones of convergence that lead to the subependymal veins and ultimately the dural sinususes.13

In this study, we found that DMVE is a common finding in neurosarcoidosis, though not as yet recognized as a distinct cerebrovascular manifestation.5 It was significantly more common in men, consistent with cerebrovascular manifestations of sarcoidosis being more frequent in this group.6 DMVE came to our attention owing to its conspicuousity on SWI, a sequence that is now widely available and was originally developed as a means for MR venography.14 A recent review showed 1 case with mild periatrial DMVE in a typical radial configuration on SWI; however, the presence of engorgement itself was not described.5

The pathophysiology of engorgement is uncertain but does not appear to be directly caused by downstream venous occlusion because dural sinuses and deep cerebral veins were patent in almost all our patients. Although there was no evident cortical thrombosis, we did notice a relative paucity of cortical veins along the cerebral hemispheres in some patients from both groups, which raised the question of whether abnormalities in the cortical veins could explain the appearance of DMVE. We did not find a significant difference in the number of visualized cortical veins between groups, but this could be an effect of sample size, and a difference may manifest itself in a larger population. Previous studies have proposed congestion of deep medullary veins as a potential indirect sign of dural sinus thrombosis.12,13–17 However, other than 2 cases published by Taoka et al18 and D’Amore et al,17 most reports do not convincingly demonstrate the characteristic parallel or radial anatomy seen in our patients. Comparison with such studies is limited because they lacked SWI. In our cohort, 1 patient with DMVE had chronic nonocclusive thrombus in the torcular, and we do not know whether it may have contributed to vascular engorgement. Thrombus can also show prominent hypointense signal on SWI18 and could potentially be difficult to distinguish from venous engorgement solely on the basis of that sequence. Although attributing our finding to venous engorgement rather than thrombosis was relatively straightforward based on its SWI appearance and lack of “blooming” artifacts, we also confirmed it by the corresponding contrast enhancement.

There was a higher incidence of perivascular space involvement in the group of patients with DMVE than in those without. Neurosarcoidosis is thought to spread to the CNS via the hematicogenous route and has a tendency to disseminate along perivascular spaces, though the reason for this particular distribution is unknown.19 Recent studies have drawn attention to the presence of a glial-based vascular or “glymphatic” pathway for cerebral clearance of solutes and metabolic by-products that is heavily dependent on aquaporin-4 water channels.20–24 In vivo and ex vivo experiments have shown rapid periarterial influx of CSF driven by arterial pulsations into the brain parenchyma, subsequent exchange with interstitial fluid, and final paravascular clearance along draining veins.23 Whether the glymphatic system plays a role in patients with neurosarcoidosis who have parenchymal or perivascular disease has not been established to date, and we do not know whether such a pathway could have influenced the development of DMVE. There is also significant controversy regarding the direction of interstitial fluid clearance and the specific anatomic space where it occurs, with other studies demonstrating primarily intramural outflow along the basement membranes of arteries and not veins.25 This is an area of intense research,26 and it is likely that evidence of the role of the glymphatic system in the pathogenesis of autoimmune and inflammatory disorders of the CNS will continue to accumulate in the near future.

Histopathologically, granulomatous infiltration of arterial and venous walls and perivascular tissues in neurosarcoidosis can be indistinguishable from primary CNS angiitis.5 Notably, venous involvement is more common around the ventricles, territory drained by the medullary veins. In some cases, there may be an inflammatory infiltrate with extensive endothelial damage in the absence of granulomas.28 These pathologic alterations may result in narrowing or obliteration of the vessel lumina19 and may possibly contribute to the engorged appearance of deep medullary veins through some degree of venous impedance.

Previous reports of primary CNS angiitis have shown a similar pattern of radial enhancement of deep medullary veins.29,30 However, it is difficult to assess how much of the linear enhancement in those patients was related to venous engorgement versus perivascular disease because no SWI was performed and findings resolved after treatment. In our study, contrast enhancement was likely a combination of perivascular disease superimposed on engorged vessels. While most patients with DMVE did not show discrete perivascular nodular enhancement, small intramural or transmural changes may have been present but beyond the capabilities of conventional MR imaging to resolve. Furthermore, there was no difference in leptomeningeal enhancement between patients with and without DMVE, and those with marked leptomeningeal disease burden were not more likely to fall into either category.

Deep medullary veins can also be prominent in ischemic stroke, in which mild prominence of deep medullary veins has been linked to hypoperfusion and poor outcomes.31,32 In that setting, they are presumed to be a manifestation of an increased regional oxygen extraction fraction leading to elevated deoxyhemoglobin in the draining veins. Studies have also suggested that this finding may be a predictor of hemorrhagic transformation in patients treated with intravenous tissue plasminogen activator.33,34 A similar appearance has also been described in Moyamoya disease, in which it has been correlated with severity.35 However, this so-called “brush sign” is relatively subtle, and none of the published cases have shown the degree of tortuosity and engorgement that was evident in our patients, in whom the process appears to be longstanding and potentially irreversible. Therefore, it is unlikely that the presence of DMVE is a direct result of perfusion changes in neurosarcoidosis. Nevertheless, we did not perform perfusion imaging, and additional research may be worthwhile.

Intracranial hemorrhage is rare in neurosarcoidosis and typically presents as microhemorrhages, likely a reflection of small-vessel disease.5,7,36 Hemorrhage is thought to result from destruction of the vessel wall by granulomatous inflammation, and previous report documented venous rupture on histopathology.36 In our study, most patients with DMVE had microhemorrhages. These were significantly more common in this group and did not seem to be an effect of patient age. Notably, there was 1
instance of macrohemorrhage that occurred in a patient with DMVE.

Hydrocephalus is seen in 10% of patients with neurosarcoidosis and is associated with high mortality. It can result from decreased CSF resorption, obstruction from meningeal or subependymal disease, or adhesions with ventricular entrapment.

We did explore whether patients with DMVE had worse neurologic outcomes, but there was no significant difference in modified Rankin Scale scores at initial evaluation or follow-up.

The main limitations of this study are inherent in its retrospective nature, with heterogeneity in follow-up times and treatment paradigms. Studies were performed on different field magnets, which likely had an effect on the conspicuity of DMVE. Additionally, conventional postcontrast MR imaging likely underestimates vascular/perivascular disease in the background of engorged vessels. Finally, sample size was relatively small, and it is possible that specific clinical associations may come to light in larger studies.

In conclusion, DMVE is a frequent manifestation of neurosarcoidosis and was seen in about one-third of patients. It does not appear to be secondary to venous thrombosis in most patients and could be an indirect effect of venous and perivenous inflammation resulting in increased venous impedance. In our cohort, this finding was associated with an increased prevalence of microhemorrhages and hydrocephalus, but patients with this finding did not have worse neurologic outcomes. Being a relatively common finding, DMVE might prompt the reader to consider a diagnosis of neurosarcoidosis in challenging cases.


REFERENCES


34. Hermier M, Nighoghossian N, Derex L, et al. Hypointense transce-